• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Xspray Pharma

15.26 SEK

0.00 %

Less than 1K followers

XSPRAY

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
-37.84 %
-45.50 %
-50.10 %
-50.10 %
-66.12 %
-60.37 %
-83.77 %
-48.04 %

Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.

Read more
Market cap
723.58M SEK
Turnover
873.08K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

11/2
2027

Annual report '26

Press release2026-06-26 08:35

Xspray Pharma lämnar regulatorisk uppdatering om sina amerikanska läkemedelskandidater Nilopki® och Dasynoc® samt fortsatta framsteg hos kontraktstillverkaren NerPharMa

Xspray Pharma
Press release2026-06-26 08:35

Xspray Pharma provides regulatory update on its US product candidates Nilopki® and Dasynoc® and notes continued progress with its third-party manufacturer NerPharMa

Xspray Pharma
Xspray, Audiocast, Press Release, 2026
Webcast2026-06-08 15:00

Xspray, Audiocast, Press Release, 2026

Xspray Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-06-05 16:48

Xspray Pharma bjuder in till telefonkonferens gällande Nilopki™

Xspray Pharma
Press release2026-06-05 16:48

Xspray Pharma to host a conference call regarding Nilopki™

Xspray Pharma
Regulatory press release2026-06-05 00:56

Xspray Pharma mottar CRL från amerikanska FDA för Nilopki™

Xspray Pharma
Regulatory press release2026-06-05 00:56

Xspray Pharma Receives CRL from U.S. FDA for Nilopki™

Xspray Pharma
Press release2026-06-03 16:50

Xspray Pharmas anställda deltar fullt ut i bolagets långsiktiga incitamentsprogram, signalerande stark framtidstro

Xspray Pharma
Press release2026-06-03 16:50

Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead

Xspray Pharma
Regulatory press release2026-05-12 11:40

Kommuniké från årsstämma i Xspray Pharma AB (publ) 12 maj 2026

Xspray Pharma
Regulatory press release2026-05-12 11:40

Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026

Xspray Pharma
Regulatory press release2026-05-04 12:08

Finansinspektionen: Flaggningsmeddelande i XSpray Pharma AB (publ)

Xspray Pharma
Regulatory press release2026-04-30 13:00

Nytt antal aktier och röster i Xspray Pharma efter nyemission april 2026

Xspray Pharma
Regulatory press release2026-04-30 13:00

New number of shares and votes in Xspray Pharma after new share issue April 2026

Xspray Pharma
Regulatory press release2026-04-28 08:00

Delårsrapport första kvartalet 2026

Xspray Pharma
Regulatory press release2026-04-28 08:00

Interim Report First Quarter 2026

Xspray Pharma
Third party research2026-04-24 08:48

Xspray Pharma: Summer PDUFA dates put launch within reach - Edison

Xspray Pharma is close to achieving commercialisation, with two FDA decisions expected this summer. The oversubscribed rights issue (securing SEK113m in gross proceeds) will remove the principal financing overhang, and any future financing needs are ...

Xspray Pharma
Regulatory press release2026-04-23 08:00

Xsprays företrädesemission övertecknad – övertilldelningsemission fullt utnyttjad

Xspray Pharma
Regulatory press release2026-04-23 08:00

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

Xspray Pharma
Press release2026-04-14 16:10

FDA accepterar handelsnamnet Nilopki® för Xsprays läkemedelskandidat XS003 (nilotinib)

Xspray Pharma